SynthesisOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
Dupilumab Extended Interval Dosing in Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-analysis.
Synthesis in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether extending the dupilumab dosing interval beyond the standard every-two-weeks (Q2W) regimen maintains clinical, radiologic, and biomarker control in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). DATA SOURCES: PubMed, Scopus, Cochrane Library, and Web of Science were systematically searched using predefined terms related to CRSwNP and dupilumab, with the final search in September 2025. Reference lists of included studies were also screened. REVIEW
methodsEligible studies enrolled adults with CRSwNP who transitioned from dupilumab 300 mg Q2W to extended intervals (≥Q4W). Two reviewers independently screened, extracted data, and assessed risk of bias using RoB2 and NIH tools. Random-effects meta-analyses synthesized sinonasal, radiologic, and biomarker outcomes. Subgroup analysis also compared switching after 6 versus 12 months of standard-dosing induction period.
resultsNineteen studies met the inclusion criteria, and nine contributed to quantitative synthesis. Across 1075 patients, extended interval dosing preserved disease control. Pooled mean differences (Q4W vs Q2W) showed non-significant changes in 22-item Sinonasal Outcome Test (SNOT-22) (-0.56), nasal congestion (-0.73), olfaction (+0.23), nasal polyp score (-0.29), and Lund-Mackay score (-1.25). Eosinophils decreased significantly (-0.13 × 10
conclusionDupilumab interval extension to Q4W maintains clinical stability after 6 to 12 months of standard dosing, with potential for longer intervals in selected patients. Further controlled trials are required to define optimal tapering strategies and identify predictors of successful dose spacing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.